Stock Price Targets and Analyst Ratings

Stay on top of the latest U.S. and international stock analyst recommendations with our up-to-date list of stock price targets and analyst ratings. This page tracks newly issued analyst ratings, price targets, upgrades, downgrades, and other broker actions to help you see how Wall Street analysts view the companies you follow. Use these ratings to compare sentiment, spot shifts in outlook, and make more informed investment decisions.

On This Page:About Stock Ratings

Company	Action	Brokerage	Analyst	Current Price	Price Target	Rating
AA Alcoa	Target Lowered by	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nick Giles Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$49.90 +2.5%	$92.00 ➝ $80.00	Buy
AAL American Airlines Group	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$17.75 -0.9%	$16.00 ➝ $25.00	Positive
AAL American Airlines Group	Downgraded by	Melius Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$17.75 -0.9%	$19.00	Buy ➝ Hold
ABCL AbCellera Biologics	Upgraded by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Wasserman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.87 -3.0%	$11.00	Hold ➝ Buy
ACAD ACADIA Pharmaceuticals	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$25.77 -0.8%		Outperform
ADBE Adobe	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tal Liani Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$218.07 -0.8%	$190.00	Buy ➝ Underperform
AER Aercap	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$153.42 +3.8%	$170.00 ➝ $176.00	Positive
AER Aercap	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Ma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$153.42 +3.8%	$164.00 ➝ $179.00	Overweight
AFL Aflac	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$120.45 -0.4%	$99.00 ➝ $98.00	Underweight
AGIO Agios Pharmaceuticals	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Stranahan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.39 -0.5%	$40.00 ➝ $46.00	Buy
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad) Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. See which companies control the supply chain behind this emerging tech
AGIO Agios Pharmaceuticals	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.39 -0.5%	$36.00 ➝ $41.00	Buy
AGIO Agios Pharmaceuticals	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$37.39 -0.5%		Sector Perform
AHR American Healthcare REIT	Initiated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$53.98 -1.9%	$61.00	Overweight
AJG Arthur J. Gallagher & Co.	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$249.98 -1.0%		Overweight
ALAR Alarum Technologies	Reiterated by	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$3.08 -51.5%		Buy ➝ Neutral
ALGT Allegiant Travel	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$115.62 -2.6%	$85.00 ➝ $132.00	Neutral
ALGT Allegiant Travel	Upgraded by	Melius Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$115.62 -2.6%	$160.00	Hold ➝ Buy
ALK Alaska Air Group	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$50.37 -1.4%	$50.00 ➝ $70.00	Positive
ALL Allstate	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$248.46 -0.7%	$203.00 ➝ $213.00	Underweight
AMGN Amgen	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$366.44 -2.1%	$327.00 ➝ $340.00	Hold
AMRZ Amrize	Reiterated by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keith Hughes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$54.02 +0.7%	$65.00 ➝ $48.00	Buy ➝ Hold
AON AON	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$356.70 -0.2%	$372.00 ➝ $382.00	Equal Weight
APP AppLovin	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$543.79 +3.2%	$571.00 ➝ $575.00	Overweight
APP AppLovin	Reiterated by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	James Callahan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$543.79 +3.2%		Overweight
ARLO Arlo Technologies	Initiated by	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$13.20 +1.7%		Outperform
ASAN Asana	Reiterated by	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Walravens Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.23 -1.5%	$15.00	Market Outperform
ASB Associated Banc	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Shaw Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.66 +0.1%		Overweight
ASIC Ategrity Specialty	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.01 -1.6%	$26.00 ➝ $28.00	Overweight
ASND Ascendis Pharma A/S	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$267.92 -2.4%		Outperform
ATOS Atossa Genetics	Initiated by	Rodman & Renshaw Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$2.28 +7.5%	$12.00	Buy
AVAV AeroVironment	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Herbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$176.84 -7.4%	$210.00	Outperform
AXP American Express	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Ma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$356.18 +1.2%	$322.00 ➝ $364.00	Equal Weight
AXSM Axsome Therapeutics	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$242.60 -0.7%		Outperform
BEAM Beam Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick R. Trucchio Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$35.32 +1.5%	$80.00	Buy
BFH Bread Financial	Upgraded by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Ma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$103.71 +1.5%	$70.00 ➝ $104.00	Underweight ➝ Equal Weight
BFH Bread Financial	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Nash Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$103.71 +1.5%	$94.00 ➝ $108.00	Neutral
BIIB Biogen	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$208.46 -3.5%		Outperform
BKU BankUnited	Target Lowered by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Shaw Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$49.49 +1.9%	$53.00 ➝ $52.00	Equal Weight
BNZL Bunzl	Target Raised by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 2,666 +0.3%	GBX 2,200 ➝ GBX 2,600	Sector perform
BOH Bank of Hawaii	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Shaw Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$83.08 +0.4%	$86.00 ➝ $88.00	Equal Weight
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad) Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. See which companies control the supply chain behind this emerging tech
BPOP Popular	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Shaw Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$168.69 +0.9%		Overweight
BRO Brown & Brown	Target Raised by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$68.42 -2.3%	$72.00 ➝ $76.00	Equal Weight
BSBR Banco Santander Brasil	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Domingos Falavina Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.29 +1.9%	$7.00 ➝ $6.50	Overweight
CCS Century Communities	Downgraded by	Zelman & Associates Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$66.98 -4.3%		Neutral ➝ Underperform
CENX Century Aluminum	Target Lowered by	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nick Giles Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$46.68 +6.7%	$86.00 ➝ $74.00	Buy
CF CF Industries	Target Lowered by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vincent Andrews Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$113.22 +2.4%	$135.00 ➝ $115.00	Equal Weight
CHRD Chord Energy	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gabe Daoud Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$111.59 -1.5%	$185.00 ➝ $170.00	Buy
CHTR Charter Communications	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Cahall Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$135.44 -1.3%	$170.00 ➝ $160.00	Underweight
CLF Cleveland-Cliffs	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexander Hacking Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.79 -0.7%	$11.00 ➝ $10.00	Neutral
CLVT Clarivate	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$2.46 -5.2%		Underweight
CMC Commercial Metals	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alexander Hacking Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$62.73 +1.6%	$85.00 ➝ $75.00	Buy
CMCSA Comcast	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Steven Cahall Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$23.38 -1.7%	$29.00 ➝ $28.00	Underweight
CNC Centene	Target Raised by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$66.02 -2.7%	$60.00 ➝ $75.00	Overweight
COP ConocoPhillips	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nitin Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$103.56 -1.1%	$150.00 ➝ $146.00	Outperform
CRNX Crinetics Pharmaceuticals	Reiterated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Josh Schimmer Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.03 -0.5%		Overweight ➝ Neutral
CRNX Crinetics Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.03 -0.5%	$81.00 ➝ $85.00	Buy ➝ Neutral
CRNX Crinetics Pharmaceuticals	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Skorney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$42.03 -0.5%	$62.00 ➝ $85.00	Outperform
CRST Crest Nicholson	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 69.80	GBX 95	Outperform
CRTO Criteo	Reiterated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$23.17 +21.4%		Buy
CSL Carlisle Companies	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keith Hughes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$366.85 +0.0%	$360.00 ➝ $340.00	Hold
CSX CSX	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Moore Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$48.81 -0.2%	$49.00 ➝ $53.00	Outperform
CVI CVR Energy	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nitin Kumar Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$28.87 +1.4%	$35.00 ➝ $28.00	Underperform
CVS CVS Health	Target Raised by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$102.13 -2.5%	$100.00 ➝ $110.00	Overweight
DAL Delta Air Lines	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$91.70 -1.1%	$78.00 ➝ $108.00	Positive
DB Deutsche Bank Aktiengesellschaft	Target Set by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$37.04 +3.3%	$43.00
DCH American Axle & Manufacturing	Reiterated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rajat Gupta Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.51 +7.3%	$8.00	Neutral
DHI D.R. Horton	Upgraded by	Zelman & Associates Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$156.58 -1.3%		Neutral ➝ Outperform
DIS Walt Disney	Reiterated by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Barton Crockett Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$97.40 -2.1%	$126.00	Buy
DOC Healthpeak Properties	Initiated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$21.75 -0.6%	$23.00	Overweight ➝ Equal Weight
DPZ Domino's Pizza	Target Lowered by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jon Tower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$305.91 -1.8%	$365.00 ➝ $335.00	Neutral
DSRLF DiaSorin	Downgraded by	BNP Paribas Exane Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$81.00		Neutral ➝ Underperform
DUOL Duolingo	Target Set by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$129.72 +3.1%	$82.00	Underweight
ECL Ecolab	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashish Sabadra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$283.69 +0.1%	$337.00	Outperform
EG Everest Group	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$373.36 +0.5%		Overweight
ELV Elevance Health	Target Raised by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$408.35 -2.3%	$400.00 ➝ $450.00	Overweight
ENLT Enlight Renewable Energy	Target Lowered by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jon Windham Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$89.03 +5.7%	$123.00 ➝ $115.00	Buy
EPC Edgewell Personal Care	Target Raised by	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Susan Anderson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$26.75 -1.7%	$32.00 ➝ $34.00	Buy
EWBC East West Bancorp	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Shaw Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$131.61 +1.8%		Overweight
EXEL Exelixis	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$55.53 -0.6%		Sector Perform
EXEL Exelixis	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$55.53 -0.6%	$54.00 ➝ $56.00	Hold
FAF First American Financial	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Ma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$70.11 +0.9%		Overweight
FCNCA First Citizens BancShares	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Nash Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$2,117.35 +1.6%	$2,100.00 ➝ $2,340.00	Neutral
FHB First Hawaiian	Target Raised by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Nash Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$30.34 +1.2%	$27.00 ➝ $30.00	Sell
FIG Figma	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tal Liani Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$21.08 -1.2%	$30.00	Neutral ➝ Buy
G Genpact	Target Lowered by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Koning Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$28.97 -0.4%	$45.00 ➝ $38.00	Neutral
GILD Gilead Sciences	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$129.61 -1.3%	$157.00 ➝ $156.00	Buy
GLNG Golar LNG	Target Set by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Mackay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$49.56 +1.1%	$66.00	Conviction-Buy
GLW Corning	Reiterated by	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Martin Yang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$194.74 -1.0%		Outperform
HCA HCA Healthcare	Target Lowered by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$417.00 +1.6%	$588.00 ➝ $525.00	Overweight
HG Hamilton Insurance Group	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$34.46 +0.1%		Overweight
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad) Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. See which companies control the supply chain behind this emerging tech
HON Honeywell International	Target Lowered by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chigusa Katoku Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$231.18 +0.6%	$260.00 ➝ $250.00	Overweight
HUM Humana	Target Raised by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Sarah James Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$393.00 -0.9%	$264.00 ➝ $300.00	Neutral
HWC Hancock Whitney	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$75.05 +0.6%		Overweight
IDYA IDEAYA Biosciences	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$39.37 +4.6%	$65.00 ➝ $63.00	Buy
IFCZF Intact Financial	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$210.67 +0.4%		Overweight
IHRT iHeartMedia	Target Lowered by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jessica Reif Cohen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.22 -3.7%	$6.00 ➝ $5.00	Neutral
INCY Incyte	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$115.62 -1.1%		Sector Perform
INR Infinity Natural Resources	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Scott Hanold Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$12.28 -1.8%	$27.00	Outperform
ITUB Itau Unibanco	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Domingos Falavina Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$8.30 +2.2%	$9.00 ➝ $10.00	Overweight
ITV ITV	Downgraded by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 76.60 -6.4%	GBX 104 ➝ GBX 85	Neutral
IVVD Invivyd	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Shrader Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$0.83 -6.7%		Buy
JAN JAN	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.34 +0.7%		Overweight
JAZZ Jazz Pharmaceuticals	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$244.17 +0.3%	$256.00 ➝ $254.00	Buy
JBLU JetBlue Airways	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$6.06 +0.7%	$5.00 ➝ $6.00	Neutral
JXN Jackson Financial	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$109.42 +4.7%		Overweight
KC Kingsoft Cloud	Initiated by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yang Liu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.13 +0.3%	$15.00	Overweight
KIGRY Kion Group	Upgraded by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$12.51 +5.6%		Overweight
KLR Keller Group	Upgraded by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 3,320 +23.8%	GBX 2,550 ➝ GBX 3,150	Buy
LBRX LB Pharmaceuticals	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Rudy Li Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$33.41 -0.1%	$45.00	Outperform
LEGN Legend Biotech	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$28.04 -6.3%		Outperform
LENZ LENZ Therapeutics	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Caufield Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.60 -4.9%		Buy
LGO Largo	Target Lowered by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Heiko F. Ihle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$0.73 -6.7%	$2.80 ➝ $2.40	Buy
LGO Largo	Target Set by	National Bank Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$0.73 -6.7%	$2.40
LLY Eli Lilly and Company	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Schott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1,200.89 -1.1%	$1,300.00 ➝ $1,400.00	Overweight
LSEG London Stock Exchange Group	Downgraded by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 9,018 +1.9%		Buy
LUV Southwest Airlines	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$50.81 +1.1%	$44.00 ➝ $55.00	Neutral
LVO LiveOne	Reiterated by	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$5.45 -3.7%		Buy
MA Mastercard	Target Raised by	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Koning Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$533.39 -1.1%	$660.00 ➝ $680.00	Outperform
MCO Moody's	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Silber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$498.84 +1.7%	$489.00 ➝ $515.00	Market Perform
MEDP Medpace	Reiterated by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Windley Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$565.09 +1.3%	$490.00 ➝ $515.00	Buy ➝ Hold
MET MetLife	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$90.43 +0.4%		Overweight
META Meta Platforms	Upgraded by	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Hans Engel Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$600.29 +3.0%		Hold ➝ Buy
MGX Metagenomi	Target Lowered by	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Keay Nakae Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.25 -0.8%	$7.00 ➝ $5.00	Buy
MGY Magnolia Oil & Gas	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gabe Daoud Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.04 -0.6%	$34.00 ➝ $32.00	Hold
MHO M/I Homes	Downgraded by	Zelman & Associates Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$152.22 -2.9%		Outperform ➝ Neutral
MIRM Mirum Pharmaceuticals	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Walter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$121.91 -2.9%		Outperform
MRNA Moderna	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Luca Issi Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$81.80 +2.6%		Sector Perform
MRVL Marvell Technology	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srini Pajjuri Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$249.27 +1.6%	$360.00	Outperform
MSTR Strategy	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Dan Dolev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$100.77	$265.00 ➝ $213.00	Outperform
MTCH Match Group	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Gawrelski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$37.67 -0.6%	$38.00 ➝ $41.00	Equal Weight
MTH Meritage Homes	Downgraded by	Zelman & Associates Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$79.79 -2.5%		Outperform ➝ Neutral
NET Cloudflare	Upgraded by	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Patrick Colville Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$247.46 +2.1%	$225.00 ➝ $300.00	Sector Perform ➝ Sector Outperform
NNOX Nano-X Imaging	Reiterated by	Alliance Global Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ben Haynor Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$1.32 +1.5%	$5.00 ➝ $3.00	Buy ➝ Neutral
NSRGY Nestle	Upgraded by	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$104.09 -1.3%		Hold ➝ Buy
NTRS Northern Trust	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ebrahim Poonawala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$181.14 +2.6%	$190.00 ➝ $200.00	Buy
NU NU	Target Raised by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yuri Fernandes Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$14.04 +3.1%	$18.00 ➝ $20.00	Overweight
NUAI New Era Energy & Digital	Initiated by	B. Riley Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nick Giles Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.76 -0.4%	$10.00	Buy
NUAI New Era Energy & Digital	Target Set by	New Street Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Derrick Whitfield Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.76 -0.4%	$10.00
NUVB Nuvation Bio	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.58 -2.1%	$12.00 ➝ $13.00	Buy
NVR NVR	Upgraded by	Zelman & Associates Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$6,676.25 -1.1%		Neutral ➝ Outperform
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad) Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. See which companies control the supply chain behind this emerging tech
NXT Nextpower	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christine Cho Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$115.03 +1.9%		Overweight
OHI Omega Healthcare Investors	Initiated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$49.00 -0.8%	$51.00	Equal Weight ➝ Underweight
ONB Old National Bancorp	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jared Shaw Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$26.45 +1.7%		Overweight
ONC BeOne Medicines	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Leonid Timashev Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$309.46 +4.0%		Outperform
ONC BeOne Medicines	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$309.46 +4.0%	$413.00 ➝ $416.00	Buy
ONDS Ondas	Target Lowered by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Austin Bohlig Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.82 +5.5%	$23.00 ➝ $19.00	Buy
PANW Palo Alto Networks	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Cikos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$357.53 +2.7%	$350.00 ➝ $425.00	Buy
PFG Principal Financial Group	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$112.55 +1.5%		Underweight
PFSI PennyMac Financial Services	Downgraded by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Ma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$83.66 +0.2%	$93.00	Overweight ➝ Equal Weight
PINS Pinterest	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.24 +0.7%	$28.00 ➝ $30.00	Overweight
PTCT PTC Therapeutics	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$85.44 +2.6%		Sector Perform
PTGX Protagonist Therapeutics	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Srikripa Devarakonda Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$131.50 -0.1%	$121.00 ➝ $145.00	Buy
RACE Ferrari	Initiated by	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Emmanuel Rosner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$392.08 +1.8%		Outperform
RDDT Reddit	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$200.67 +3.1%	$176.00 ➝ $187.00	Equal Weight
REGN Regeneron Pharmaceuticals	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$649.81 -0.7%	$778.00 ➝ $769.00	Buy
REGN Regeneron Pharmaceuticals	Upgraded by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Wasserman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$649.81 -0.7%	$185.00	Hold ➝ Buy
RGA Reinsurance Group of America	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alex Scott Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$224.15 +1.4%		Overweight
RGEN Repligen	Upgraded by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$141.46 -0.7%		Buy
RGEN Repligen	Upgraded by	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Wasserman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$141.46 -0.7%	$185.00	Hold ➝ Buy
RNR RenaissanceRe	Reiterated by	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$323.28 -0.9%		Hold
RXST RxSight	Reiterated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	David Saxon Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$5.60 -0.2%	$11.00	Buy
RYTM Rhythm Pharmaceuticals	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lisa Walter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$111.68 -2.2%		Outperform
SAIA Saia	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Wadewitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$417.89 +0.3%	$493.00 ➝ $527.00	Buy
SBRA Sabra Healthcare REIT	Initiated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$19.73 -2.1%	$21.00	Equal Weight
SHOP Shopify	Reiterated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tal Liani Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$120.14 +0.6%	$150.00	Buy
SKWD Skyward Specialty Insurance Group	Target Raised by	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Paul Newsome Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$60.20 -2.0%	$55.00 ➝ $68.00	Overweight
SLM SLM	Reiterated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Terry Ma Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.53 -0.3%	$30.00 ➝ $26.00	Overweight ➝ Equal Weight
SM SM Energy	Target Lowered by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Janela Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$26.36 -1.8%	$38.00 ➝ $37.00	Outperform
SM SM Energy	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gabe Daoud Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$26.36 -1.8%	$39.00 ➝ $37.00	Buy
SM SM Energy	Target Lowered by	Stephens Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Mike Scialla Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$26.36 -1.8%	$61.00 ➝ $52.00	Overweight
SNAP Snap	Target Lowered by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$4.76 -1.7%	$7.00 ➝ $5.00	Equal Weight
SPCX SpaceX	Initiated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Edison Yu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$255.00	Buy
SPCX SpaceX	Initiated by	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Colin Canfield Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$246.00	Overweight
SPCX SpaceX	Initiated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Herbert Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$225.00	Outperform
SPCX SpaceX	Initiated by	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Harned Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$239.00	Outperform
SPCX SpaceX	Initiated by	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$160.42 -1.0%		Outperform
SPCX SpaceX	Initiated by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Gesuale Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$800.00	Strong-Buy
SPCX SpaceX	Initiated by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ronald Epstein Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$235.00	Buy
SPCX SpaceX	Initiated by	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$160.42 -1.0%	$225.00	Overweight
SPCX SpaceX	Initiated by	Moffett Nathanson Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Julie Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$131.00	Neutral
SPCX SpaceX	Initiated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Hodulik Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$210.00	Buy
SPCX SpaceX	Initiated by	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jonathan Siegmann Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$190.00	Buy
SPCX SpaceX	Initiated by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ryan Koontz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$200.00	Buy
SPCX SpaceX	Initiated by	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Adam Jonas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$300.00	Negative ➝ Overweight
SPCX SpaceX	Initiated by	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Godyn Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$200.00	Buy
SPCX SpaceX	Initiated by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ken Gawrelski Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$230.00	Overweight
SPCX SpaceX	Initiated by	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eric Sheridan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$160.42 -1.0%	$205.00	Buy
SPCX SpaceX	Initiated by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$160.42 -1.0%	$200.00	Outperform
SPGI S&P Global	Target Raised by	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Jeffrey Silber Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$447.27 +1.7%	$495.00 ➝ $505.00	Outperform
SPGI S&P Global	Target Lowered by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ashish Sabadra Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$447.27 +1.7%	$560.00 ➝ $510.00	Outperform
Trump Takes Emergency Action - Plus Elon Musk's New Venture (Ad) Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Trump has issued emergency support to accelerate the rollout, and it's already live in multiple states. The Financial Times reports Sam Altman is personally calling people to build this for OpenAI. A few little-known companies control the entire supply chain - meaning anyone who wants access must go through them. Their stocks are available to buy right now. See which companies control the supply chain behind this emerging tech
SR Spire	Reiterated by	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gabriel Moreen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$78.42 -1.6%	$88.00	Outperform
SSB SouthState Bank	Downgraded by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$100.93 +0.8%		Buy ➝ Neutral
SSNLF Samsung Electronics	Downgraded by	Erste Group Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$140.00		Buy ➝ Hold
STT State Street	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ebrahim Poonawala Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$175.57 +2.9%	$160.00 ➝ $190.00	Neutral
SYF Synchrony Financial	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erika Najarian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$77.04 +0.9%	$77.00 ➝ $84.00	Neutral
SYY Sysco	Downgraded by	Melius Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$84.35 -0.6%		Hold ➝ Sell
TBPH Theravance Biopharma	Downgraded by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Douglas Tsao Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$17.00 +0.4%	$15.00 ➝ $17.00	Buy ➝ Neutral
TBTG The Beauty Tech Group	Target Raised by	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		GBX 364 +9.3%	GBX 500 ➝ GBX 550	Buy
TDOC Teladoc Health	Target Raised by	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Allen Lutz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$9.29 +1.0%	$9.00 ➝ $10.50	Buy
TFC Truist Financial	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erika Najarian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$51.45 +0.9%	$58.00 ➝ $55.00	Buy ➝ Neutral
TFII TFI International	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Wadewitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$140.74 +1.1%	$110.00 ➝ $154.00	Neutral
TLX Telix Pharmaceuticals	Reiterated by	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Robert Burns Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$12.15 +2.4%	$20.00	Buy
TSLA Tesla	Target Raised by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tom Narayan Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$419.77 +6.7%	$475.00 ➝ $500.00	Outperform
TTWO Take-Two Interactive Software	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$258.41 +1.3%	$287.00 ➝ $289.00	Overweight
U Unity Software	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$29.62 +1.0%	$35.00 ➝ $36.00	Overweight
UAL United Airlines	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$132.50 -0.6%	$135.00 ➝ $172.00	Positive
ULCC Frontier Group	Target Raised by	Susquehanna Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Christopher Stathoulopoulos Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.81 +3.0%	$4.50 ➝ $7.00	Neutral
UPST Upstart	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kyle Peterson Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$34.33 -1.3%	$37.00 ➝ $40.00	Buy
UPST Upstart	Reiterated by	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Vincent Caintic Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$34.33 -1.3%	$43.00	Buy
USB U.S. Bancorp	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Erika Najarian Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$62.83 +1.8%	$58.00 ➝ $66.00	Neutral
VNET VNET Group	Initiated by	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Peter Milliken Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$7.81 -1.4%	$12.50	Buy
VRTX Vertex Pharmaceuticals	Reiterated by	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Abrahams Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$529.59 +0.3%		Outperform
VTR Ventas	Initiated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$92.18 -0.4%	$99.00	Overweight ➝ Equal Weight
WELL Welltower	Initiated by	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Richard Hightower Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$232.70 -1.4%	$254.00	Overweight ➝ Equal Weight
WHK WhiteHawk Income	Initiated by	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Freeman Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$26.75 -2.3%	$34.00	Strong-Buy
WM Waste Management	Upgraded by	Canadian Imperial Bank of Commerce Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kevin Chiang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$228.99 -0.6%	$244.00	Neutral ➝ Outperformer
WSM Williams-Sonoma	Target Raised by	KeyCorp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Bradley Thomas Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$223.71 -1.7%	$230.00 ➝ $250.00	Overweight
WTFC Wintrust Financial	Reiterated by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Nicholas Holowko Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$162.79 +1.0%	$170.00	Buy ➝ Neutral
WULF TeraWulf	Target Raised by	Rosenblatt Securities Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Chris Brendler Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.21 +4.9%	$27.00 ➝ $30.00	Buy
WULF TeraWulf	Target Raised by	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	John Todaro Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$22.21 +4.9%	$28.00 ➝ $33.00	Buy
XEL Xcel Energy	Target Set by	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		$80.37 -1.9%	$101.00
XNCR Xencor	Target Lowered by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$14.89 -0.7%	$29.00 ➝ $27.00	Buy
XPO XPO	Target Raised by	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Thomas Wadewitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$206.71 +0.2%	$236.00 ➝ $257.00	Buy
ZG Zillow Group	Target Raised by	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Alec Brondolo Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$32.95 -1.4%	$45.00 ➝ $46.00	Equal Weight
ZYME Zymeworks	Target Raised by	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gregory Renza Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	$25.33 -3.7%	$28.00 ➝ $31.00	Buy

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 09:19 AM ET.

Stock Ratings and Recommendations: Understanding Analyst Ratings

Written by MarketBeat Staff

Key Points

Stock analysts give ratings to companies based on their research and insights.
Analysis comes from the buy side (fund companies, investment managers) or sell side (brokers, banks).
Analysts use different methodologies, so investors should always look into why a particular rating was given.
5 stocks we like better than EXA)

You'll often hear a particular stock called a "buy" or "sell," but who exactly makes these calls? Ratings and recommendations come from stock analysts, who research different securities and work for various institutions, brokerage firms and other financial companies.

Analyst ratings are designed to give additional information to investors beyond just what the company is saying, but are analyst ratings reliable? In this article, we'll discuss how to read analyst ratings, what goes into their decision-making process and how potential conflicts of interest influence analyst stock ratings.

What Are Analyst Ratings?

A stock rating is a simple heuristic given by analysts who review the firm's financial statements, listen to conference calls, chat with company executives and compare the stock to others in the industry or sector. Finally, an analyst uses all this information to produce a simple recommendation and price target.

When a public analyst goes on CNBC or the "Wall Street Journal" to give a "buy" or "sell" rating on a particular stock, they take all their research and pare it down into a simple designation. While there's no true consensus on what constitutes a buy or sell rating, an analyst usually does have "skin in the game" when devising ratings.

Ratings often pair with price targets, which put a hard number on what the analysts believe the company stock should be worth. So, for example, you might see an analyst report something like, "Buy NVIDIA Inc. (NASDAQ: NVDA), price target $350," which means that particular analyst believes investors should buy NVDA shares up to a price of $350 per share.

Analyst ratings infographic: What you need to know

What Does a Stock Analyst Do?

A stock analyst is a market professional with the skills to interpret financial data and the connections within companies to speak on the record with higher-ups. Analysts generally fall into one of two different camps: buy-side or sell-side. These positions will seem similar, but they tend to be employed by various institutions and have different responsibilities in their particular market "territories."

Buy-side analysts: Analysts on the buy side tend to work for funds, such as ETF providers or hedge funds. They don't dig as deeply into company financial data or conference calls as sell-siders. Instead, they focus on general areas or industries where their funds have vested interests. In addition, buy-side analysts often forge relationships with sell-side analysts for individual stock research. A buy-side analyst's primary goal is to find and utilize the most accurate and dependable sell-side analysts.
Sell-side analysts: If buy-side analysts work for funds (i.e., institutions that buy securities), you can probably guess which type of institution employs sell-side analysts. Brokers, banks and other firms that sell securities to investors use sell-side analysts to give reports to the public. While buy-side analysts also give ratings and price targets, the reported "buy" and "sell" ratings in financial media typically come from folks on the sell side.

Buy and sell-side analysts often use different rating systems when making their recommendations. You might even find two sell-side analysts with similar "buy" recommendations with vastly different price targets in the same stock. As a result, you'll need to familiarize yourself with the various methodologies analysts use to utilize their research correctly.

What Ratings Do Analysts Give?

Stock analyst ratings don't follow a strict structure, although most have roughly the same grading system for the securities they review. The labels may differ slightly (i.e., overweight vs. outperform), but the five most common analyst ratings go like this.

Buy

Analysts bullish on a particular security will give it a "buy" rating and set a price target above the current market price. In addition, if the analyst considers the stock one of the best in the industry or sector, you'll sometimes see a "strong buy" rating attached.

Hold

A "hold" rating is typically the lowest rating a sell-side analyst gives a stock. "Hold" means the analyst projects the stock to meet the return of the market averages, making it an unspectacular investment. Stocks rated "hold" may still have a price target above the current price, but it's not likely to surpass the return of a major index like the S&P 500.

Sell

Analysts are usually apprehensive about giving a stock a "sell" rating. For example, suppose a "hold" rating indicates indecision over the stock's future. In this scenario, a "sell" rating is issued when an analyst finds something unappealing, such as questionable accounting tactics or cratering sales growth.

Underperform

Analysts won't always give a firm "buy" or "sell" rating on stock but will instead label it "underperform" or "outperform." "Underperform" means the analyst expects the stock not to keep up with the market. It doesn't necessarily mean the analyst predicts a crash but indicates a lack of confidence in the shares.

Outperform

"Outperform" is the opposite of "underperform," meaning the analyst expects the stock to do better than the market average. It's usually considered a less confident rating than "buy."

Example of an Analyst Rating

You can use MarketBeat Analyst Ratings to find ranges and aggregates from buy- and sell-side analysts across the financial media. For example, here's a stock that analysts usually love: Alphabet Inc. (NASDAQ: GOOG).

Overview of stock analysis on GOOG Using MarketBeat's tools, you can find ratings from prominent analysts from multiple periods. Alphabet is currently labeled a "moderate buy" based on MarketBeat's consensus from 17 analysts. You'll get the consensus price target and the highest and lowest from the analysts surveyed.

Marketbeat's tools detailing analyst ratings

Looking at analyst recommendations over time is another helpful tool. For example, you can view the different levels of coverage over the last few years, which analysts changed their ratings and how the price targets vary from month to month. If an analyst can't get a good read on a particular stock they've been covering, they might choose to withhold their grade, which is one reason why the number of available ratings can change over time.

Overview of analyst ratings on MarketBeat Analysts from both sides of the aisle can be found on MarketBeat, ranging from large firms like JPMorgan Chase and Co. (NYSE: JPM) to smaller investment banks like Roth Capital. Some institutions like UBS Group offer both buy-side and sell-side ratings and analysis. These graphs show that even analysts with similar ratings can have vastly different price targets, so always understand the reasoning behind an analyst's view.

How to Use Analyst Ratings

Here are a few pointers on incorporating analyst ratings into your investment research.

Step 1: Don't rely on a single analyst.

Using an array of analysts (buy- and sell-side) gives inventors the most possible information. Don't just look for analysts with similar opinions as yourself — ensure you understand the pros and cons of each investment you make by incorporating positive and negative views, if possible.

Step 2: Compare analyst ratings across the industry or sector.

It's easy to slap a "buy" rating on a stock and predict a winner, but comparing stocks against others in the sector can offer insight into the rating. For example, if a stock is rated "buy" in the information technology sector, but a dozen others are rated "strong buy" by the same analyst, where is your capital best served?

Step 3: Consider your own goals and risk tolerance.

You might find stocks rated "strong buy" in your research in sectors you wish to avoid. That's fine! There are thousands of securities across dozens of industries in the public markets, and you don't need to purchase every share that comes with a "buy" rating. Instead, stick to your investment plan.

Step 4: Don't stubbornly stick to your original assessments.

Following your investment plan and using analyst ratings as guidelines are practical steps, but things can change over time. Today's "strong buy" stocks could be "strong sell" stocks down the road. Using an aggregate of analysts' ratings can help investors view stocks from a higher level. For example, if the number of "buy" ratings on a stock drops 40% over a few years, you might want to take a closer look at that particular company.

Why Are Analyst Ratings Important?

Checking out analyst ratings isn't a necessary step for investing, but it can be helpful for those looking to dig deep into an asset's prospects. Analyst research often has quotes from company executives, questions from conference calls and in-depth reporting on the company's balance sheet, income statement and other essential documents. Analysis like this is complex for individual investors to do on their own, especially considering how frequently analysts interact with the executives they cover. But access often comes with a downside, which we discuss more below.

How Accurate Are Analyst Ratings?

Both buy and sell-side analysts strive for accuracy because giving consistently wrong commendations can be hazardous for job security. However, investors should be aware that analysts might not always have the best interest of the retail investor at heart when making their recommendations.

For starters, being an analyst requires access to company employees and management. Analysts typically ask questions during conference calls and speak with C-suite executives on the record about their firms' prospects. Executives usually don't want to hear adverse reports about their companies, so analysts are incentivized to paint a rosy picture to retain access. The SEC has been questioning the authenticity of analyst ratings (especially on the sell-side) since 2002 when it asked bluntly, "Why are there so few sell ratings?"

Of course, there are other areas of the securities analysis market to face scrutiny. If you recall, during the 2008 financial crisis, the biggest credit rating agencies were all held to the fire due to claims that conflicts of interest influenced their ratings. The biggest rating agencies in the world were accused of "misrepresenting the risks associated with mortgage-backed securities." Remember, analyst ratings aren't spat out by computer algorithms but by living, breathing people who may have agendas other than providing the most precise and accurate reports on a company's future prospects.

Analyst Ratings Can Guide Investors, but Don't Treat Them as Gospel

Consider each type of investment research or advice in collaboration. Even the most accurate and thoughtful analysts get things wrong, plus ratings are frequently besieged with conflicts of interest. But analyst coverage does offer research that's difficult to get elsewhere, and using an array of analyst reports can give investors a deeper understanding of the securities they buy.

FAQs

Still have questions about analyst ratings? Here are a few answers to some common points of discussion:

What are analyst ratings?

Analyst ratings are the "buy" and "sell" labels, plus price targets, that investment researchers attach to specific securities. These ratings are based on financial data, earnings reports and conversations with company executives.

Should you trust analyst ratings?

Analyst ratings provide plenty of helpful information, but you shouldn't use an analyst's "buy" rating as the sole reason you purchase a security. Analysts aren't immune to conflicts of interest or outside parties' influence, so ensure you always understand why a stock was labeled a "buy" or "sell."

What does an analyst rating tell you about a stock?

Ratings give investors the analyst's overall opinion about a particular stock and price targets based on the company's valuation and prospects. Analysts often attend conference calls, ask questions and provide in-depth information about companies that are difficult to acquire elsewhere.

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Price Forecasts for Popular Stocks

Top Stock Recommendations by Brokerage

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Stock Price Targets and Analyst Ratings